DUPIXENT is the only dual inhibitor of IL-4 and IL-13 signaling and is approved for 3 indications.

To continue to a site, select an indication:
Uncontrolled Moderate-to-Severe

Atopic Dermatitis

For Patients Ages 6+ Years

Moderate-to-Severe

Asthma

With an Eosinophilic Phenotype or Oral Corticosteroid Dependent Asthma
NOW APPROVED FOR AGES 6-11 YEARS

For Patients Ages 6+ Years

Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Inadequately Controlled

Chronic Rhinosinusitis With Nasal Polyposis

For Patients Ages 18+ Years

The DUPIXENT 200 mg and 300 mg Pre-filled Pen are available for your appropriate patients aged 12+ years

DUPIXENT is indicated:

  • for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
  • as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.

DUPIXENT MyWay
ENROLLMENT FORMS

FOR DERMATOLOGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ALLERGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ENT SPECIALISTS/
PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form

CoverMyMeds support is available for DUPIXENT

CoverMyMeds provides additional enrollment and PA process-related support for DUPIXENT. Live support is available at 866-452-5017 or covermymeds.com.